Metsera Inc, a clinical-stage biotechnology company, said on Thursday that it had priced its initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company, are expected to be about $275.0 million.
The company’s common stock is expected to be listed on the Nasdaq Global Select Market under the ticker symbol “MTSR” on January 31st.
BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor are serving as joint bookrunners for the offering, which is expected to close on February 3rd.
The underwriters have been granted a 30-day option to buy up to additional 2,291,666 shares of common stock at the IPO price less underwriting discounts and commissions.
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
